KYOWA KIRIN CO. LTD./ JP3256000005 /
| 2024-06-10 8:00:42 AM | Chg. +0.200 | Volume | Bid5:51:10 PM | Ask5:51:10 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 15.900EUR | +1.27% | 0 Turnover: 0.000 |
15.900Bid Size: 315 | 16.500Ask Size: 304 | 8.65 bill.EUR | - | - |
GlobeNewswire
05-23
Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first pote...
GlobeNewswire
05-21
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapano...
GlobeNewswire
05-16
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
GlobeNewswire
05-08
Pharming Group reports first quarter 2024 financial results and provides business update
GlobeNewswire
05-07
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Ir...
GlobeNewswire
05-03
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024...
GlobeNewswire
05-02
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-02
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire
05-01
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Ch...
GlobeNewswire
04-23
AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval...
GlobeNewswire
04-10
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as Pr...
GlobeNewswire
03-25
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
03-20
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Ap...
